-
admin
Posts
Marintec Innovation Conference 2024: Explore Renewable Energy and Low Carbon Shipping
HONG KONG, June 17, 2024 /PRNewswire/ — Building on the success of its inaugural edition during Marintec China 2017, Marintec Innovation Conference is back and...
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented...
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses in CLL patients were rapid...
Tan Xuguang: Enter South Korea, Full Focus on Business in the “Doorstep” Market
SEOUL, South Korea, June 16, 2024 /PRNewswire/ — In alignment with the global strategic development of Shandong Heavy Industry, with a focus on bolstering “doorstep” export...
Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
The study met its primary endpoint of overall survival with a 41% reduction in the risk of death in people with relapsed or refractory (R/R)...
Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional ENERGIZE Poster Presentation Highlights Improvements...
IASO Bio Presented New Data of FUCASO® (Equecabtagene Autoleucel) for the Treatment of High-risk Newly Diagnosed Multiple Myeloma in Oral Presentation at EHA 2024
SHANGHAI and NANJING, China and SAN JOSE, Calif., June 15, 2024 /PRNewswire/ — IASO biotechnology (“IASO Bio”), a biopharmaceutical company engaged in discovering, developing, manufacturing...
CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024
SHANGHAI, June 15, 2024 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of...
China’s Hainan FTP Cements ties with South Korea and the United States
HAIKOU, China, June 15, 2024 /PRNewswire/ — A report from Hainan International Media Center: Recently, a delegation from China’s southern Hainan Province visited South Korea...
Astronergy TOPCon products’ testified by TÜV Rheinlands’ three world’s firsts
SHANGHAI, June 15, 2024 /PRNewswire/ — Seeing the world’s first IEC TS 63126:2020 (2 PfG 2971) photovoltaic module certificate, the world’s first IEC TS 63126 PV...